Astrazeneca (AZN) Interest & Investment Income (2009 - 2026)

Astrazeneca's Interest & Investment Income history runs 18 years deep, the most recent figure standing at $80.0 million for Q2 2026.

• In Q2 2026, Interest & Investment Income rose 17.65% year-over-year to $80.0 million; the TTM figure through Jun 2026 stood at $373.0 million (down 6.52% YoY), while the FY2025 annual figure was $360.0 million, down 21.4% from the prior year.
• Interest & Investment Income for Q2 2026 stood at $80.0 million, up from $73.0 million in the prior quarter.
• The five-year high for Interest & Investment Income was $183.0 million in Q3 2024, with the low at $15.0 million in Q3 2022.
• The 5-year median for Interest & Investment Income is $79.0 million (2023), against an average of $79.4 million.
• The sharpest annual moves came in 2022 and 2025: Interest & Investment Income soared 4400.0% in 2022, then tumbled 53.55% in 2025.
• Astrazeneca's Interest & Investment Income stood at $45.0 million in 2022, then jumped by 140.0% to $108.0 million in 2023, then plunged by 40.74% to $64.0 million in 2024, then soared by 110.94% to $135.0 million in 2025, then plunged by 40.74% to $80.0 million in 2026.
• Business Quant data shows AZN's Interest & Investment Income at $80.0 million in Q2 2026, $73.0 million in Q1 2026, and $135.0 million in Q4 2025.